DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR MIGLITOL
Clinical Trials for Miglitol
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | National Eye Institute (NEI) | Phase 3 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
| NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | SmithKline Beecham | Phase 3 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
| NCT00032487 | Glycemic Control and Complications in Diabetes Mellitus Type 2 (VADT) | Completed | VA Office of Research and Development | Phase 3 | This study is a prospective, 2-arm, randomized controlled trial to determine whether glycemic control, achieved through intensification of treatment, is effective in preventing clinical macrovascular complications in patients with type 2 DM who are no longer responsive to oral agents alone. The study consists of a two-year accrual period and five years of follow-up (7 years total) of 1700 patients across 20 centers. We have powered the study to detect a 21% reduction in the primary event rate. Additional study goals are to determine whether the expenditures, discomfort, and adverse effects associated with intensive intervention are justified in terms of their clinical benefits, considering both macrovascular and microvascular complications. |
| NCT00213070 | Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | Phase 3 | The purpose of this study is evaluate the clinical efficacy and safety of Miglitol in patients with Type2 Diabetes Mellitus with treated insulin. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Miglitol
Condition Name
Condition MeSH
Clinical Trial Locations for Miglitol
Trials by Country
Clinical Trial Progress for Miglitol
Clinical Trial Phase
Clinical Trial Sponsors for Miglitol
Sponsor Name
